(DYN) Dyne Therapeutics - Overview
Stock: Therapeutics, Neuromuscular, Myotonic, Duchenne, Pompe
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 90.6% |
| Relative Tail Risk | -18.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 10.53 |
| Character TTM | |
|---|---|
| Beta | 1.583 |
| Beta Downside | 1.394 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.52% |
| CAGR/Max DD | 0.12 |
Description: DYN Dyne Therapeutics January 16, 2026
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage biotechnology firm that concentrates on developing disease-modifying therapies for a range of neuromuscular disorders in the United States, leveraging its proprietary FORCE platform to deliver targeted gene-editing and RNA-based treatments.
The company’s pipeline includes programs for Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Dystrophy (FSHD), Pompe disease, and other rare skeletal-, cardiac-, and metabolic-muscle indications. As of Q4 2024, Dyne reported that its lead DM1 candidate entered a Phase 1/2 dose-escalation study, while the DMD program secured a $30 million research collaboration with a major pharmaceutical partner.
From a market perspective, the global neuromuscular disease market is projected to exceed $15 billion by 2028, driven by an aging population and increasing FDA approvals for gene-therapy modalities. Dyne’s cash runway, disclosed at $85 million at the end of 2023, supports approximately 18 months of operations at its current burn rate of $4.7 million per quarter, implying a near-term need for additional financing or partnership capital to sustain its pipeline progression.
For a deeper, data-driven view of Dyne’s valuation dynamics, you may find it useful to explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -423.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.46 > 0.02 and ΔFCF/TA -14.00 > 1.0 |
| NWC/Revenue: 47.5k% < 20% (prev 18.3k%; Δ 29.2k% < -1%) |
| CFO/TA -0.43 > 3% & CFO -375.7m > Net Income -423.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (141.8m) vs 12m ago 40.57% < -2% |
| Gross Margin: 36.26% > 18% (prev 0.54%; Δ 3572 % > 0.5%) |
| Asset Turnover: 0.19% > 50% (prev 0.49%; Δ -0.30% > 0%) |
| Interest Coverage Ratio: -145.2 > 6 (EBITDA TTM -433.4m / Interest Expense TTM 3.00m) |
Altman Z'' -10.45
| A: 0.86 (Total Current Assets 806.3m - Total Current Liabilities 59.8m) / Total Assets 867.1m |
| B: -1.48 (Retained Earnings -1.28b / Total Assets 867.1m) |
| C: -0.53 (EBIT TTM -435.4m / Avg Total Assets 818.0m) |
| D: -7.32 (Book Value of Equity -1.28b / Total Liabilities 175.3m) |
| Altman-Z'' Score: -10.45 = D |
What is the price of DYN shares?
Over the past week, the price has changed by +5.10%, over one month by +4.00%, over three months by -21.36% and over the past year by +36.70%.
Is DYN a buy, sell or hold?
- StrongBuy: 7
- Buy: 6
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.1 | 106.4% |
| Analysts Target Price | 39.1 | 106.4% |
| ValueRay Target Price | 20.2 | 6.4% |
DYN Fundamental Data Overview February 03, 2026
P/EG = 0.19
Revenue TTM = 1.57m USD
EBIT TTM = -435.4m USD
EBITDA TTM = -433.4m USD
Long Term Debt = 99.1m USD (from longTermDebt, last quarter)
Short Term Debt = 5.04m USD (from shortTermDebt, last quarter)
Debt = 120.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -453.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.27b USD (2.95b + Debt 120.5m - CCE 791.9m)
Interest Coverage Ratio = -145.2 (Ebit TTM -435.4m / Interest Expense TTM 3.00m)
EV/FCF = -5.73x (Enterprise Value 2.27b / FCF TTM -397.0m)
FCF Yield = -17.46% (FCF TTM -397.0m / Enterprise Value 2.27b)
FCF Margin = -25.3k% (FCF TTM -397.0m / Revenue TTM 1.57m)
Net Margin = -27.0k% (Net Income TTM -423.8m / Revenue TTM 1.57m)
Gross Margin = 36.26% ((Revenue TTM 1.57m - Cost of Revenue TTM 1.00m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.62 (Enterprise Value 2.27b / Total Assets 867.1m)
Interest Expense / Debt = 2.41% (Interest Expense 2.90m / Debt 120.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -344.0m (EBIT -435.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.47 (Total Current Assets 806.3m / Total Current Liabilities 59.8m)
Debt / Equity = 0.17 (Debt 120.5m / totalStockholderEquity, last quarter 691.8m)
Debt / EBITDA = 1.05 (negative EBITDA) (Net Debt -453.1m / EBITDA -433.4m)
Debt / FCF = 1.14 (negative FCF - burning cash) (Net Debt -453.1m / FCF TTM -397.0m)
Total Stockholder Equity = 640.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.81% (Net Income -423.8m / Total Assets 867.1m)
RoE = -66.17% (Net Income TTM -423.8m / Total Stockholder Equity 640.5m)
RoCE = -58.86% (EBIT -435.4m / Capital Employed (Equity 640.5m + L.T.Debt 99.1m))
RoIC = -49.85% (negative operating profit) (NOPAT -344.0m / Invested Capital 690.0m)
WACC = 11.36% (E(2.95b)/V(3.07b) * Re(11.75%) + D(120.5m)/V(3.07b) * Rd(2.41%) * (1-Tc(0.21)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 51.98%
Fair Price DCF = unknown (Cash Flow -397.0m)
EPS Correlation: 29.29 | EPS CAGR: 26.63% | SUE: 4.0 | # QB: 1
Revenue Correlation: 15.91 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.81 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-3.32 | Chg30d=-0.005 | Revisions Net=-1 | Growth EPS=+6.0% | Growth Revenue=+0.0%